FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213204346> ?p ?o ?g. }

• W4213204346 endingPage "237" @default.
• W4213204346 startingPage "217" @default.
• W4213204346 abstract "Dravet syndrome is a severe developmental and epileptic encephalopathy characterised by refractory seizures and cognitive dysfunction. The treatment is challenging, not least because the seizures are highly drug resistant, requiring multiple anti-seizure medications (ASMs), while some ASMs can exacerbate seizures. Initial treatments include the broad-spectrum ASMs valproate (VPA), and clobazam (CLB) in some regions; however, they are generally insufficient to control seizures. With this in mind, three adjunct ASMs have been approved specifically for the treatment of seizures in patients with Dravet syndrome: stiripentol (STP) in 2007 in the European Union and 2018 in the USA, cannabidiol (CBD) in 2018/2019 (in combination with CLB in the European Union) and fenfluramine (FFA) in 2020. These “add-on” therapies (mostly to VPA/CLB) are used as escalation therapies, with the choice dependent on availability in different countries, patient characteristics and caregiver preferences. Topiramate is also frequently used, with evidence of efficacy in Dravet syndrome, and there is anecdotal evidence of efficacy with bromide, which is frequently used in Germany and Japan. With a growing treatment landscape for Dravet syndrome, there can be practical challenges for clinicians, particularly with issues associated with polypharmacy. This practical guide provides an overview of these main ASMs including their indications/contraindications, mechanism of action, efficacy, safety and tolerability profile, dosage requirements, and laboratory and clinical parameters to be evaluated. Standard laboratory and clinical parameters include blood counts, liver function tests, serum concentrations of ASMs, monitoring the growth of children, as well as weight loss and acceleration of behavioural problems. Regular cardiac monitoring is also important with FFA as it has previously been associated with cases of cardiac valve disease when used in adults at high doses (up to 120 mg/day) in combination with phentermine as a therapy for obesity. Importantly, no signs of heart valve disease have been documented to date at the low doses used in patients with developmental and epileptic encephalopathies. In addition, potential drug–drug interactions and their consequences are a key consideration in everyday practice. Interactions that potentially require dosage adjustments to alleviate adverse events include the following: STP + CLB resulting in increased plasma concentrations of CLB and its active metabolite norclobazam may increase somnolence, and an interaction with STP and VPA may increase gastrointestinal adverse events. Cannabidiol has a bi-directional interaction with CLB producing an increase in plasma concentrations of 7-OH-CBD and norclobazam resulting in the potential for increased somnolence and sedation. In addition, CBD is associated with elevations of liver transaminases particularly in patients taking concomitant VPA. The interaction between FFA and STP requires a dose reduction of FFA. Furthermore, concomitant administration of VPA with topiramate has been associated with encephalopathy and/or hyperammonaemia. Finally, we briefly describe other ASMs used in Dravet syndrome, and current key clinical trials." @default.
• W4213204346 created "2022-02-24" @default.
• W4213204346 creator A5018035642 @default.
• W4213204346 creator A5063015953 @default.
• W4213204346 date "2022-02-14" @default.
• W4213204346 modified "2023-10-18" @default.
• W4213204346 title "A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication" @default.
• W4213204346 cites W1564863670 @default.
• W4213204346 cites W1926532831 @default.
• W4213204346 cites W1945928592 @default.
• W4213204346 cites W1951203427 @default.
• W4213204346 cites W1964990613 @default.
• W4213204346 cites W1965127622 @default.
• W4213204346 cites W1979296345 @default.
• W4213204346 cites W1984224337 @default.
• W4213204346 cites W1989957365 @default.
• W4213204346 cites W2005107590 @default.
• W4213204346 cites W2007691763 @default.
• W4213204346 cites W2019073856 @default.
• W4213204346 cites W2020497106 @default.
• W4213204346 cites W2028253822 @default.
• W4213204346 cites W2030113059 @default.
• W4213204346 cites W2034988455 @default.
• W4213204346 cites W2037693985 @default.
• W4213204346 cites W2057554220 @default.
• W4213204346 cites W2063801230 @default.
• W4213204346 cites W2064752349 @default.
• W4213204346 cites W2083064460 @default.
• W4213204346 cites W2089159188 @default.
• W4213204346 cites W2093392404 @default.
• W4213204346 cites W2097891845 @default.
• W4213204346 cites W2101383744 @default.
• W4213204346 cites W2111114355 @default.
• W4213204346 cites W2140968331 @default.
• W4213204346 cites W2147974822 @default.
• W4213204346 cites W2153855789 @default.
• W4213204346 cites W2160234096 @default.
• W4213204346 cites W2160266876 @default.
• W4213204346 cites W2169966598 @default.
• W4213204346 cites W2170194739 @default.
• W4213204346 cites W2218400884 @default.
• W4213204346 cites W2334787160 @default.
• W4213204346 cites W2396520718 @default.
• W4213204346 cites W2399319535 @default.
• W4213204346 cites W2402833179 @default.
• W4213204346 cites W2531145217 @default.
• W4213204346 cites W2563189157 @default.
• W4213204346 cites W2606646389 @default.
• W4213204346 cites W2620218661 @default.
• W4213204346 cites W2736365965 @default.
• W4213204346 cites W2763605737 @default.
• W4213204346 cites W2767422484 @default.
• W4213204346 cites W2790754741 @default.
• W4213204346 cites W2888643586 @default.
• W4213204346 cites W2897171837 @default.
• W4213204346 cites W2902262849 @default.
• W4213204346 cites W2904308873 @default.
• W4213204346 cites W2905603477 @default.
• W4213204346 cites W2918466418 @default.
• W4213204346 cites W2924269608 @default.
• W4213204346 cites W2925073929 @default.
• W4213204346 cites W2945843636 @default.
• W4213204346 cites W2953834411 @default.
• W4213204346 cites W2955589096 @default.
• W4213204346 cites W2962402170 @default.
• W4213204346 cites W2965877292 @default.
• W4213204346 cites W2976958970 @default.
• W4213204346 cites W2978062341 @default.
• W4213204346 cites W2981192969 @default.
• W4213204346 cites W2989575580 @default.
• W4213204346 cites W2996672198 @default.
• W4213204346 cites W2998177544 @default.
• W4213204346 cites W2998796218 @default.
• W4213204346 cites W3003169441 @default.
• W4213204346 cites W3007463076 @default.
• W4213204346 cites W3009130471 @default.
• W4213204346 cites W3011456989 @default.
• W4213204346 cites W3011777852 @default.
• W4213204346 cites W3023605125 @default.
• W4213204346 cites W3030374821 @default.
• W4213204346 cites W3030769523 @default.
• W4213204346 cites W3031017926 @default.
• W4213204346 cites W3039362800 @default.
• W4213204346 cites W3042990227 @default.
• W4213204346 cites W3049895572 @default.
• W4213204346 cites W3051775721 @default.
• W4213204346 cites W3087269728 @default.
• W4213204346 cites W3091395003 @default.
• W4213204346 cites W3093626132 @default.
• W4213204346 cites W3109613337 @default.
• W4213204346 cites W3113518007 @default.
• W4213204346 cites W3127937043 @default.
• W4213204346 cites W3131763102 @default.
• W4213204346 cites W3134743067 @default.
• W4213204346 cites W3136007168 @default.
• W4213204346 cites W3144446845 @default.
• W4213204346 cites W3162698004 @default.
• W4213204346 cites W3164802563 @default.

• next